NEO — NeoGenomics, Inc.

NeoGenomics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $186.7 million, an 11% increase year-over-year, exceeding guidance.
• Clinical Revenue: $171 million, up 14% year-over-year, driven by volume growth of 6% and an 8% increase in Average Unit Price (AUP).
• Adjusted EBITDA: $9 million, a 27% increase from Q1 2025, with an adjusted EBITDA margin expansion of 60 basis points.
• Nonclinical Revenue: $15.5 million, down 15% year-over-year, primarily due to expected softness in the pharma sector.
• Cash Position: Ended the quarter with $146 million in cash; cash used in operations decreased to $8.1 million from $25.3 million in the prior year.

2. Strategic Updates and Business Highlights

• NeoGenomics is focused on the oncology market, emphasizing its strong position in hematology and community hospital partnerships.
• The company reentered the Minimal Residual Disease (MRD) market with the launch of RaDaR ST, targeting a $20 billion opportunity.
• Five Next-Generation Sequencing (NGS) products launched in 2023 contributed 25% of clinical revenue in Q1.
• The Pathline acquisition has strengthened the company’s presence in the Northeast, with growth at 1.5x the national average.
• The commercial strategy includes expanding the sales force and enhancing the portfolio with new tests and technologies.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Increased to $797 million to $803 million, up from previous guidance of $793 million to $801 million.
• Quarterly Growth Expectations: Anticipated revenue growth of approximately 9% year-over-year in Q2, followed by 9% to 10% in Q3, and above 10% in Q4.
• Adjusted EBITDA Guidance: Maintained at $55 million to $57 million, reflecting year-over-year growth of 27% to 31%.
• The company expects continued gross margin expansion of approximately 100 basis points year-over-year.

4. Bad News, Challenges, or Points of Concern

• Nonclinical Business Decline: Revenue from the nonclinical segment decreased by 15%, with expectations of continued low to mid-single-digit declines throughout 2026.
• Gross Margin Pressure: Adjusted gross margin decreased by 80 basis points due to the Pathline acquisition and higher freight costs.
• High-Volume, Low-Value Contracts Exit: The strategic exit from these contracts has impacted volumes, but the company expects this to stabilize over time.
• Market Penetration Risks: Concerns about sustaining NGS growth rates amid competitive pressures and the need for continued adoption of new products.

5. Notable Q&A Insights

• NGS Growth Sustainability: Management expressed confidence in sustaining NGS growth rates, citing strong early performance from the PanTracer Liquid Biopsy and overall market demand.
• Sales Force Expansion: The addition of sales resources is seen as a critical driver for future growth, particularly in the community oncology setting.
• RaDaR ST Market Potential: The company is optimistic about the potential for RaDaR ST, with expectations of doubling the eligible patient population if additional indications receive reimbursement.
• Payer Mix for Liquid Biopsy: Currently, approximately 40% of liquid biopsy orders are from Medicare, with expectations for gradual improvement in commercial payer coverage.

Overall, NeoGenomics demonstrated strong financial performance in Q1 2026, with promising growth in clinical revenue and strategic initiatives aimed at expanding its oncology testing portfolio. However, challenges remain in the nonclinical segment and gross margin pressures, which the company is actively addressing.